Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1Breast 1

Conditions

Breast Neoplasms 11Colorectal Neoplasms 3Prostatic Neoplasms 2Neoplasms 2Lung Neoplasms 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Diseases 1Patient Preference 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma 1Communication 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

pembrolizumab 163Carboplatin 146Paclitaxel 125Cyclophosphamide 94130-nm albumin-bound paclitaxel 66Capecitabine 64Gemcitabine 54Doxorubicin 50Albumin-Bound Paclitaxel 45Taxes 42atezolizumab 41Cisplatin 39sacituzumab govitecan 34Nivolumab 34olaparib 32Epirubicin 32Specimen Handling 28Docetaxel 28eribulin 27Bevacizumab 26durvalumab 25Drug Therapy 25Biopsy 24camrelizumab 23Magnetic Resonance Spectroscopy 22toripalimab 19Radiotherapy 17spartalizumab 16Everolimus 15veliparib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Focus Groups × Breast × Clear all
NCT04118062 2025-09-19

Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR)

Institut Curie

Phase NA Completed
128 enrolled
BreastDermatologic

Uveal Melanoma, Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡